Association ofCYP2C19*2and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients-Reference-Cited by-同舟云学术

Association ofCYP2C19*2and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients

Published:2016-03-08 Issue:6 Volume:81 Page:1142-1152
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Lim Joanne Siok Liu¹,Sutiman Natalia²,Muerdter Thomas E.³,Singh Onkar¹,Cheung Yin Bun⁴⁵,Ng Raymond Chee Hui⁶,Yap Yoon Sim⁶,Wong Nan Soon⁷,Ang Peter Cher Siang⁷,Dent Rebecca⁶,Schroth Werner³,Schwab Matthias⁸,Chowbay Balram¹²⁹

Affiliation:

1. Laboratory of Clinical Pharmacology, Division of Medical Sciences; Humphrey Oei Institute of Cancer Research, National Cancer Centre; Singapore

2. Clinical Pharmacology; SingHealth; Singapore

3. Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology; Stuttgart and University Tubingen; Germany

4. Center for Quantitative Medicine; Duke-NUS Graduate Medical School; Singapore

5. Department of International Health; University of Tampere; Finland

6. Division of Medical Oncology; National Cancer Centre; Singapore

7. OncoCare Cancer Centre, Mount Elizabeth Novena Medical Centre; Singapore

8. Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and Department of Clinical Pharmacology; University Hospital; Tubingen Germany

9. Office of Clinical Sciences; Duke-NUS Graduate Medical School; Singapore

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12886/fullpdf

Reference42 articles.

1. Tamoxifen in the treatment of breast cancer;Osborne;N Engl J Med,1998

2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Early Breast Cancer Trialists' Collaborative Group (EBCTCG);Lancet,2005

3. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment;Jin;J Natl Cancer Inst,2005

4. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients;Lim;Br J Clin Pharmacol,2011

5. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine;Stearns;J Natl Cancer Inst,2003

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of CYP2D6 and its polymorphic forms on the metabolism of tamoxifen in therapy of luminal forms of breast cancer;Reports of Vinnytsia National Medical University;2024-03-14

2. Association between genetic polymorphisms in cytochrome P450 enzymes and survivals in women with breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis;Expert Reviews in Molecular Medicine;2022

3. Pharmacogenetics of common SNP affecting drug metabolizing enzymes: comparison of allele frequencies between European and Malaysian/Singaporean;Drug Metabolism and Personalized Therapy;2021-03-19

4. Pharmacogenetics of common SNP affecting drug metabolizing enzymes: comparison of allele frequencies between European and Malaysian/Singaporean;Drug Metabolism and Personalized Therapy;2021-03-18

5. Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy;Cancers;2021-02-12